Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Energy & Commerce chair

This article was originally published in The Tan Sheet

Executive Summary

Rep. Joe Barton (R-Tex.) could be named to fill chairman seat at the House Energy & Commerce Committee as early as week of Feb. 9, staffers say. Barton is lead candidate to replace Billy Tauzin (R-La.), who steps down as chair effective Feb. 16. Tauzin is rumored to be the top choice to head the Pharmaceutical Research & Manufacturers of America. Under Tauzin, committee held hearings on dietary supplement safety, with a focus on ephedra, in 2003. As chair of the Commerce/Oversight & Investigations Subcommittee in mid to late 1990s, Barton examined a number of health-related issues...

You may also be interested in...

PhRMA CEO Tauzin Takes Over Jan. 3: PR Focus Begins At The Top

PhRMA's new management team under CEO Billy Tauzin will place a high priority on communications and partnerships with other stakeholders in healthcare policy debates

Barton to head Energy & Commerce

Rep. Joe Barton (R-Tex.) will succeed Rep. Billy Tauzin (R-La.) as chairman of the House Committee on Energy & Commerce, the committee confirms Feb. 26. Barton was named as a potential replacement by congressional staffers following Tauzin's announcement to step down from the position (1"The Tan Sheet" Feb. 9. 2004, In Brief). Tauzin left the position while negotiating a move to become CEO of the Pharmaceutical Research & Manufacturers of America. Tauzin's discussions with the trade group have since ended, his office reports on Feb. 26; the former committee chairman is not seeking re-election and does not intend to make decisions about future opportunities until after he leaves Congress, according to his staff...

MedPAC’s Part B Options Include ‘Value-Based’ Payment During Accelerated Approval

Medicare Payment Advisory Commission also considering reviving least costly alternative policy in some way, but remains relatively hesitant about changes to ASP+6%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts